NP / PA
District Hospital Partners L P
District Hospital Partners L P was paid $136.25M by Medicaid between Jan 2018 and Dec 2024, across 412 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 13% of everything it billed.
33Billing provider infoDISTRICT HOSPITAL PARTNERS L P
WASHINGTON, DC 20037
WASHINGTON, DC 20037
33aNPI1487640207assigned 09/27/2005
33bProvider typeFamily Nurse Practitioner
28Total paid$136.25M
24GClaims1,835,526
24DCodes billed412
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in District of Columbia
Rank by total paid#1 of 27
Median peer was paid$19K
This provider vs. median7,220×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 297,778 | $17.05M | |
| 2019 | 338,843 | $20.65M | |
| 2020 | 295,118 | $16.57M | |
| 2021 | 305,160 | $18.79M | |
| 2022 | 254,635 | $23.15M | |
| 2023 | 197,802 | $22.12M | |
| 2024incomplete | 146,190 | $17.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 78,361 | 31,430 | $17.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.4% | 46,090 | 40,880 | $10.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 45,458 | 41,180 | $9.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.2% | 37,835 | 33,003 | $8.50M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.9% | 15,158 | 13,018 | $8.03M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 12,350 | 11,288 | $3.34M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 3,814 | 3,494 | $2.81M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 34,837 | 15,011 | $2.81M |
| 19083 | 1.9% | 1,584 | 1,482 | $2.62M | |
| 97535 | Self-care/home management training, each 15 minutes | 1.8% | 10,880 | 7,414 | $2.51M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.7% | 3,329 | 3,079 | $2.25M |
| 77386 | 1.6% | 4,740 | 422 | $2.24M |
400 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 9,816 | $2.20M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 25,995 | $2.16M |
| 59025 | Fetal non-stress test | 1.4% | 6,302 | $1.97M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 20,147 | $1.92M |
| 97161 | 1.4% | 9,582 | $1.85M | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.3% | 2,195 | $1.81M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.3% | 1,251 | $1.73M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 5,379 | $1.71M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 15,394 | $1.64M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 7,200 | $1.59M |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 13,429 | $1.59M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 14,905 | $1.52M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 4,517 | $1.37M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,636 | $1.30M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 9,156 | $1.28M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,979 | $1.28M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 11,961 | $1.19M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,358 | $1.17M |
| 76642 | <1% | 5,578 | $1.09M | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,954 | $1.09M |
| 97597 | <1% | 5,790 | $1.08M | |
| G0378 | Hospital observation service, per hour | <1% | 7,295 | $1.03M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,364 | $980K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,084 | $935K |
| 97016 | <1% | 7,893 | $906K | |
| 97162 | <1% | 4,360 | $897K | |
| 76830 | Ultrasound, transvaginal | <1% | 7,702 | $806K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 10,294 | $790K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,849 | $780K |
| 97116 | <1% | 6,763 | $736K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,004 | $701K |
| 64483 | <1% | 565 | $690K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,798 | $684K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,467 | $674K |
| 72197 | <1% | 1,401 | $673K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,559 | $632K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,188 | $629K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,054 | $628K |
| 97165 | <1% | 2,758 | $582K | |
| 70496 | <1% | 1,595 | $546K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,329 | $543K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 484 | $518K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,801 | $490K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,573 | $480K |
| 64493 | <1% | 649 | $478K | |
| 77412 | <1% | 562 | $453K | |
| 93971 | <1% | 3,391 | $445K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,052 | $435K |
| 29581 | <1% | 2,043 | $416K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,801 | $408K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,301 | $381K |
| 76641 | <1% | 1,481 | $366K | |
| 72141 | <1% | 1,560 | $362K | |
| 71250 | <1% | 3,437 | $359K | |
| 73630 | <1% | 7,746 | $356K | |
| 76536 | <1% | 2,159 | $349K | |
| 97166 | <1% | 1,830 | $348K | |
| 77066 | Tomosynthesis, mammo | <1% | 5,507 | $335K |
| 74183 | <1% | 801 | $330K | |
| 76775 | <1% | 2,319 | $312K | |
| 97018 | <1% | 2,571 | $311K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 2,976 | $295K |
| 77336 | <1% | 2,729 | $289K | |
| 77065 | Tomosynthesis, mammo | <1% | 4,745 | $264K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 52,938 | $252K |
| 93970 | <1% | 1,343 | $233K | |
| 93975 | <1% | 1,643 | $217K | |
| 76801 | <1% | 2,683 | $214K | |
| 77014 | <1% | 6,228 | $192K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 932 | $189K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 48,352 | $187K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,581 | $185K |
| 70486 | <1% | 3,020 | $166K | |
| 80053 | Comprehensive metabolic panel | <1% | 32,549 | $154K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 799 | $149K |
| 20610 | <1% | 478 | $146K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 541 | $145K |
| 19081 | <1% | 83 | $144K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 416 | $144K |
| 77280 | <1% | 522 | $142K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 10,159 | $130K |
| 10060 | <1% | 498 | $127K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,024 | $126K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,050 | $121K |
| 74174 | <1% | 838 | $121K | |
| 73221 | <1% | 481 | $120K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 587 | $119K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,710 | $117K |
| 73130 | <1% | 4,327 | $109K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,745 | $108K |
| 90715 | <1% | 3,548 | $108K | |
| 73030 | <1% | 4,272 | $104K | |
| G0465 | Autologous platelet rich plasma (prp) or other blood-derived product for diabetic chronic wounds/ulcers, using an fda-cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment) | <1% | 60 | $103K |
| 73562 | <1% | 2,836 | $101K | |
| 70491 | <1% | 469 | $98K | |
| 72100 | <1% | 2,444 | $90K | |
| 83880 | <1% | 9,445 | $79K | |
| 73564 | <1% | 3,339 | $75K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 6,198 | $74K |
| 76870 | <1% | 676 | $73K | |
| 73610 | <1% | 3,694 | $72K | |
| 58571 | <1% | 13 | $70K | |
| 97163 | <1% | 437 | $67K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 79,904 | $66K |
| 72040 | <1% | 1,283 | $62K | |
| 10160 | <1% | 216 | $61K | |
| 74178 | <1% | 213 | $57K | |
| 77290 | <1% | 172 | $56K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,227 | $55K |
| 71271 | <1% | 299 | $54K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,763 | $54K |
| 15271 | <1% | 28 | $52K | |
| 73110 | <1% | 2,466 | $51K | |
| 77334 | <1% | 340 | $51K | |
| 97598 | <1% | 710 | $49K | |
| 73502 | <1% | 2,216 | $48K | |
| 36561 | <1% | 13 | $47K | |
| 84484 | <1% | 27,812 | $46K | |
| 77080 | <1% | 464 | $43K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 99,726 | $40K |
| 72110 | <1% | 700 | $39K | |
| 80076 | <1% | 15,548 | $38K | |
| 70498 | <1% | 1,354 | $37K | |
| 12001 | <1% | 128 | $35K | |
| 86923 | <1% | 1,202 | $35K | |
| 87040 | <1% | 3,763 | $34K | |
| 97032 | <1% | 119 | $34K | |
| 43235 | <1% | 59 | $33K | |
| 97164 | <1% | 111 | $33K | |
| 86850 | <1% | 11,055 | $32K | |
| 78306 | <1% | 92 | $31K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,950 | $30K |
| 84702 | <1% | 7,565 | $30K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 77 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,595 | $27K |
| 70544 | <1% | 61 | $25K | |
| 64454 | <1% | 46 | $24K | |
| 88307 | <1% | 770 | $24K | |
| 72131 | <1% | 368 | $23K | |
| 20553 | <1% | 85 | $23K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 138 | $23K |
| 12011 | <1% | 85 | $22K | |
| 85379 | <1% | 3,515 | $21K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,572 | $21K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 84 | $21K |
| 88341 | <1% | 1,172 | $20K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,177 | $19K |
| 86900 | <1% | 12,018 | $19K | |
| 72070 | <1% | 555 | $18K | |
| 82962 | <1% | 28,949 | $18K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,308 | $18K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 677 | $17K |
| 81001 | <1% | 42,386 | $17K | |
| 88342 | <1% | 3,655 | $17K | |
| 73080 | <1% | 1,359 | $17K | |
| 85027 | <1% | 8,652 | $16K | |
| 72120 | <1% | 204 | $16K | |
| 83735 | <1% | 25,964 | $16K | |
| 83605 | <1% | 10,057 | $16K | |
| 92523 | <1% | 116 | $16K | |
| 20560 | <1% | 128 | $15K | |
| 80197 | <1% | 4,498 | $15K | |
| 97022 | <1% | 189 | $15K | |
| 86901 | <1% | 12,037 | $14K | |
| 77300 | <1% | 194 | $13K | |
| 73522 | <1% | 390 | $12K | |
| 73590 | <1% | 1,488 | $12K | |
| 97542 | <1% | 47 | $12K | |
| 77001 | <1% | 75 | $12K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,907 | $11K |
| 77338 | <1% | 14 | $11K | |
| 74018 | <1% | 357 | $11K | |
| 72050 | <1% | 153 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,587 | $10K |
| 80051 | <1% | 2,670 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,369 | $10K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,801 | $10K |
| 12002 | <1% | 43 | $10K | |
| 81514 | <1% | 37 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,867 | $9K |
| 97139 | <1% | 267 | $9K | |
| 82803 | <1% | 7,263 | $8K | |
| 77301 | <1% | 13 | $8K | |
| 85610 | <1% | 12,213 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,783 | $7K |
| 88304 | <1% | 875 | $7K | |
| 85730 | <1% | 8,626 | $6K | |
| 75574 | <1% | 13 | $6K | |
| 96367 | <1% | 437 | $6K | |
| 73560 | <1% | 234 | $6K | |
| 99201 | <1% | 25 | $6K | |
| 81025 | <1% | 18,049 | $6K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 105 | $6K |
| 72170 | <1% | 582 | $6K | |
| C1769 | Guide wire | <1% | 2,190 | $6K |
| 83690 | <1% | 14,208 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,675 | $6K |
| 84100 | <1% | 8,160 | $6K | |
| 87486 | <1% | 372 | $6K | |
| 88312 | <1% | 549 | $5K | |
| 62323 | <1% | 25 | $5K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 114 | $5K |
| 73700 | <1% | 33 | $5K | |
| 87507 | <1% | 142 | $4K | |
| 80061 | Lipid panel | <1% | 2,091 | $4K |
| 96376 | <1% | 5,113 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $4K |
| 87210 | <1% | 3,746 | $4K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 20 | $4K |
| 87077 | <1% | 3,174 | $4K | |
| 97760 | <1% | 34 | $4K | |
| 86803 | <1% | 401 | $4K | |
| 73140 | <1% | 348 | $4K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,660 | $4K |
| 87799 | <1% | 659 | $4K | |
| 73090 | <1% | 708 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,574 | $3K |
| 87070 | <1% | 3,564 | $3K | |
| 62322 | <1% | 12 | $3K | |
| 87581 | <1% | 372 | $3K | |
| 82565 | <1% | 10,855 | $3K | |
| 82075 | <1% | 1,800 | $3K | |
| 77470 | <1% | 14 | $3K | |
| 87497 | <1% | 540 | $3K | |
| 73552 | <1% | 315 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 12,595 | $3K |
| 88112 | <1% | 131 | $3K | |
| C1776 | Joint device (implantable) | <1% | 41 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 401 | $2K |
| 88142 | <1% | 117 | $2K | |
| 70547 | <1% | 30 | $2K | |
| 86140 | <1% | 3,184 | $2K | |
| 85014 | <1% | 4,255 | $2K | |
| 20561 | <1% | 20 | $2K | |
| 74420 | <1% | 28 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 17,741 | $2K |
| 80050 | General health panel | <1% | 679 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 372 | $2K |
| 86592 | <1% | 1,254 | $2K | |
| 76942 | <1% | 30 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,169 | $2K |
| C1729 | Catheter, drainage | <1% | 1,814 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,635 | $1K |
| 72052 | <1% | 26 | $1K | |
| 87205 | <1% | 2,512 | $1K | |
| 82570 | <1% | 2,094 | $1K | |
| 87186 | <1% | 3,380 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 79 | $1K |
| 84439 | <1% | 793 | $1K | |
| 73060 | <1% | 198 | $1K | |
| 82374 | <1% | 2,157 | $1K | |
| 74230 | <1% | 16 | $1K | |
| 90686 | <1% | 95 | $1K | |
| 85018 | <1% | 4,219 | $1K | |
| 82728 | <1% | 597 | $1K | |
| 82550 | <1% | 2,646 | $1K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 14 | $1K |
| 85651 | <1% | 2,863 | $1K | |
| 36430 | <1% | 117 | $981.39 | |
| 87640 | <1% | 28 | $896.56 | |
| 86703 | <1% | 493 | $894.05 | |
| G0008 | Administration of influenza virus vaccine | <1% | 94 | $883.49 |
| 87430 | <1% | 798 | $800.33 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,527 | $800.32 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,375 | $734.79 |
| 84481 | <1% | 376 | $712.21 | |
| 83970 | <1% | 111 | $656.41 | |
| 92610 | <1% | 30 | $648.73 | |
| 83615 | <1% | 1,349 | $594.24 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,305 | $592.72 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 862 | $563.24 |
| 82607 | <1% | 246 | $553.65 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 5,503 | $551.30 |
| 87641 | <1% | 28 | $500.78 | |
| 87116 | <1% | 27 | $491.97 | |
| 73620 | <1% | 38 | $486.89 | |
| 72128 | <1% | 16 | $479.71 | |
| 84156 | <1% | 1,462 | $442.25 | |
| 84466 | <1% | 452 | $422.80 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 836 | $384.05 |
| 83540 | <1% | 518 | $377.92 | |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | <1% | 14 | $348.22 |
| 73660 | <1% | 18 | $323.10 | |
| 87653 | <1% | 31 | $299.99 | |
| 87340 | <1% | 492 | $297.61 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,233 | $280.49 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 14 | $263.83 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,812 | $239.62 |
| 0353U | <1% | 818 | $231.94 | |
| 84132 | <1% | 998 | $228.83 | |
| 90714 | <1% | 13 | $225.26 | |
| 85045 | <1% | 442 | $213.15 | |
| 89051 | <1% | 119 | $200.23 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,251 | $197.47 |
| 87503 | <1% | 24 | $185.30 | |
| 74019 | <1% | 13 | $174.15 | |
| 86706 | <1% | 260 | $169.87 | |
| 85576 | <1% | 31 | $164.31 | |
| 64495 | <1% | 182 | $163.18 | |
| 82248 | <1% | 304 | $152.54 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,157 | $146.01 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,987 | $143.50 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,731 | $142.32 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,934 | $136.72 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 86 | $135.75 |
| 73600 | <1% | 13 | $131.02 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,103 | $117.53 |
| 87899 | <1% | 255 | $108.87 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 88 | $96.58 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 229 | $83.62 |
| 86704 | <1% | 70 | $81.36 | |
| 84295 | <1% | 816 | $78.19 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,821 | $77.40 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 691 | $74.16 |
| 88173 | <1% | 15 | $71.60 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 346 | $66.99 |
| 86308 | <1% | 66 | $64.54 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,158 | $57.86 |
| 85384 | <1% | 146 | $57.56 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 163 | $52.09 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,382 | $51.28 |
| 82436 | <1% | 50 | $49.47 | |
| A9270 | Non-covered item or service | <1% | 34,493 | $45.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,211 | $39.03 |
| 84300 | <1% | 136 | $32.15 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,671 | $30.03 |
| C1780 | Lens, intraocular (new technology) | <1% | 1,159 | $27.18 |
| 0250 | <1% | 4,368 | $24.64 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 823 | $22.23 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 489 | $17.60 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,697 | $15.59 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,785 | $13.25 |
| 87341 | <1% | 27 | $12.72 | |
| 84133 | <1% | 50 | $12.37 | |
| 87075 | <1% | 106 | $12.10 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,247 | $9.31 |
| 87102 | <1% | 63 | $5.02 | |
| J3490 | Unclassified drugs | <1% | 89 | $4.27 |
| 87206 | <1% | 26 | $2.51 | |
| 84460 | <1% | 47 | $2.13 | |
| 84550 | <1% | 41 | $1.96 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,115 | $0.87 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 187 | $0.24 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 71 | $0.01 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 19 | $0.01 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 365 | $0.01 |
| 0272 | 0% | 100 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 770 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 31 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 363 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 778 | $0.00 |
| 99152 | 0% | 248 | $0.00 | |
| 77002 | 0% | 44 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 244 | $0.00 |
| 84450 | 0% | 32 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 169 | $0.00 |
| C1765 | Adhesion barrier | 0% | 25 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 267 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| 76376 | 0% | 35 | $0.00 | |
| 85347 | 0% | 91 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 905 | $0.00 |
| 88302 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 805 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 47 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 98 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 26 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 16 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 17 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| 76937 | 0% | 13 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 13 | $0.00 |
| 76000 | 0% | 12 | $0.00 | |
| 76818 | 0% | 13 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 116 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 185 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 2,352 | $0.00 |
| 0710 | 0% | 283 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 857 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 389 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 375 | $0.00 |
| 64494 | 0% | 364 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 165 | $0.00 |
| 82330 | 0% | 15 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 135 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 391 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 46 | $0.00 |
| C1763 | Connective tissue, non-human (includes synthetic) | 0% | 237 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 27 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 12 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 50 | $0.00 |
| 77417 | 0% | 29 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 14 | $0.00 |
| 64484 | 0% | 12 | $0.00 | |
| 36416 | 0% | 18 | $0.00 | |
| 0270 | 0% | 19 | $0.00 | |
| 85390 | 0% | 19 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.